Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis.
cardiac amyloidosis
frailty
heart failure
transthyretin
wild type
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
revised:
12
07
2024
received:
12
04
2024
accepted:
02
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
aheadofprint
Résumé
Wild-type transthyretin cardiac amyloidosis (ATTRwt CA) is a common, underdiagnosed cause of heart failure (HF) in the elderly. Concurrent extracardiac amyloid infiltration might be responsible for a specific frailty phenotype. This study aims to compare the prevalence and characteristics of frailty parameters in HF patients, with or without ATTRwt CA. In a comparative cross-sectional study, we prospectively included consecutive HF patients with or without ATTRwt CA (the HF + ATTRwt+ and HF + ATTRwt- groups, respectively) between April 2018 and April 2021. Logistic regression models were used to compare the groups with regard to frailty as assessed using multidimensional geriatric tools. We included 123 patients (68 HF + ATTRwt+ and 55 HF + ATTRwt-). The mean age was 80.9 (standard deviation 6.3) years, 87% were male, 34% had left ventricular systolic dysfunction and 34% were New York Heart Association (NYHA) III. Relative to the HF + ATTRwt- group, patients in the HF + ATTRwt+ group were more likely to have shrinking [odds ratios = 2.9 (95% confidence interval, 1.1 to 1.7), P = 0.03], balance disorders [1.8 (1.1 to 2.8), P = 0.02], memory complaints [2.5, (1.0 to 5.9), P = 0.05] and overactive bladder [1.5 (1.1 to 2.2), P = 0.03], independently of age, sex, NYHA class and diabetes status. The proportion of very frail patients was higher (albeit not significantly) in the HF + ATTRwt+ group than in the HF + ATTRwt- group [2.4 (0.9 to 6.9), P = 0.10]. ATTRwt CA is associated with a specific frailty phenotype. Patients with ATTRwt CA should be screened for frailty and managed collaboratively by cardiologists and geriatricians, with a view to improving quality of life.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583‐596. doi:10.1056/NEJMra023144
Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117‐124. doi:10.1007/s10741‐015‐9480‐0
Porcari A, Bussani R, Merlo M, Varrà GG, Pagura L, Rozze D, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post‐mortem examination. Front Cardiovasc Med 2021;8:749523. doi:10.3389/fcvm.2021.749523
González‐López E, Gallego‐Delgado M, Guzzo‐Merello G, de Haro‐Del Moral FJ, Cobo‐Marcos M, Robles C, et al. Wild‐type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585‐2594. doi:10.1093/eurheartj/ehv338
Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879‐2887. doi:10.1093/eurheartj/ehx350
Lindmark K, Pilebro B, Sundström T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail 2021;8:745‐749. doi:10.1002/ehf2.13110
Brunjes DL, Castano A, Clemons A, Rubin J, Maurer MS. Transthyretin cardiac amyloidosis in older Americans. J Card Fail 2016;22:996‐1003. doi:10.1016/j.cardfail.2016.10.008
Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol Off J U S Can Acad Pathol Inc 2015;28:201‐207. doi:10.1038/modpathol.2014.102
Bartier S, Bodez D, Kharoubi M, Guellich A, Canouï‐Poitrine F, Chatelin V, et al. Association between hearing loss and hereditary ATTR amyloidosis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis 2019;26:234‐242. doi:10.1080/13506129.2019.1663814
Boyle RP, Sharan J, Schwartz G. Carpal tunnel syndrome in transthyretin cardiac amyloidosis: implications and protocol for diagnosis and treatment. Cureus 2021;13:e14546. doi:10.7759/cureus.14546
Kharoubi M, Roche F, Bézard M, Hupin D, Silva S, Oghina S, et al. Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild‐type cardiac amyloidosis. ESC Heart Fail 2021;8:1656‐1665. doi:10.1002/ehf2.13131
Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019;12:e006075. doi:10.1161/CIRCHEARTFAILURE.119.006075
Berthelot E, Broussier A, Hittinger L, Donadio C, Rovani X, Salengro E, et al. FINC‐94 network. Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure. ESC Heart Fail 2023;10:2042‐2050. doi:10.1002/ehf2.14337
Jaramillo‐Hidalgo J, Quezada‐Feijoó M, Ramos M, Toro R, Gómez‐Pavón J, Ayala‐Muñoz R. Prevalence of transthyretin cardiac amyloidosis in elderly patients diagnosed with heart failure. Rev Esp Geriatr Gerontol 2023;58:8‐14. doi:10.1016/j.regg.2022.10.005
Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez‐Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799‐2806. doi:10.1093/eurheartj/ehx589
Fine NM, McMillan JM. Prevalence and prognostic significance of frailty among patients with transthyretin amyloidosis cardiomyopathy. Circ Heart Fail 2021;14:e008105. doi:10.1161/CIRCHEARTFAILURE.120.008105
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56:M146‐M157. doi:10.1093/gerona/56.3.m146
Yang X, Lupón J, Vidán MT, Ferguson C, Gastelurrutia P, Newton PJ, et al. Impact of frailty on mortality and hospitalization in chronic heart failure: a systematic review and meta‐analysis. J Am Heart Assoc 2018;7:e008251. doi:10.1161/JAHA.117.008251
Vitale C, Jankowska E, Hill L, Piepoli M, Doehner W, Anker SD, et al. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail 2019;21:1299‐1305. doi:10.1002/ejhf.1611
Broussier A, David JP, Kharoubi M, Oghina S, Segaux L, Teiger E, et al. Frailty in wild‐type transthyretin cardiac amyloidosis: the tip of the iceberg. J Clin Med 2021;10:p3415. doi:10.3390/jcm10153415
Garcia‐Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554‐1568. doi:10.1093/eurheartj/ehab072
Rockwood K, Mogilner A, Mitnitski A. Changes with age in the distribution of a frailty index. Mech Ageing Dev 2004;125:517‐519. doi:10.1016/j.mad.2004.05.003
Oubaya N, Dramé M, Novella J‐L, Quignard E, Cunin C, Jolly D, et al. Screening for frailty in community‐dwelling elderly subjects: predictive validity of the modified SEGA instrument. Arch Gerontol Geriatr 2017;73:177‐181. doi:10.1016/j.archger.2017.07.026
Lawton MP, Brody EM. Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist 1969;9:179‐186. doi:10.1093/geront/9.3_Part_1.179
Vellas B, Villars H, Abellan G, Soto ME, Rolland Y, Guigoz Y, et al. Overview of the MNA—its history and challenges. J Nutr Health Aging 2006;10:463‐465. doi:10.1093/geront/9.3_Part_1.179
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self‐reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:M85‐M94. doi:10.1093/geronj/49.2.m85
Cesari M, Kritchevsky SB, Penninx BWHJ, Nicklas BJ, Simonsick EM, Newman AB, et al. Prognostic value of usual gait speed in well‐functioning older people‐results from the Health, Aging and Body Composition Study. J Am Geriatr Soc 2005;53:1675‐1680. doi:10.1111/j.1532‐5415.2005.53501.x
Vellas BJ, Wayne SJ, Romero L, Baumgartner RN, Rubenstein LZ, Garry PJ. One‐leg balance is an important predictor of injurious falls in older persons. J Am Geriatr Soc 1997;45:735‐738. doi:10.1111/j.1532‐5415.1997.tb01479.x
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology 2000;55:1621‐1626. doi:10.1212/wnl.55.11.1621
Hyer L, Blount J. Concurrent and discriminant validities of the geriatric depression scale with older psychiatric inpatients. Psychol Rep 1984;54:611‐616. doi:10.2466/pr0.1984.54.2.611
Haab F, Richard F, Amarenco G, Coloby P, Arnould B, Benmedjahed K, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire. Urology 2008;71:646‐656. doi:10.1016/j.urology.2007.11.100
Denfeld QE, Winters‐Stone K, Mudd JO, Gelow JM, Kurdi S, Lee CS. The prevalence of frailty in heart failure: a systematic review and meta‐analysis. Int J Cardiol 2017;236:283‐289. doi:10.1016/j.ijcard.2017.01.153
Sánchez MB, Dolores Matoso M, Aguirre MA, Mercedes Nucifora E, Marciano S, Cepeda J, et al. Prevalence of digestive manifestations in patients with amyloidosis. Amyloid 2019;26:103‐104. doi:10.1080/13506129.2019.1582492
Kharoubi M, Bodez D, Bézard M, Zaroui A, Galat A, Guendouz S, et al. Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. Amyloid 2022;29:79‐91. doi:10.1080/13506129.2021.2013193
Poterucha TJ, Kurian D, Raiszadeh F, Teruya S, Elias P, Kogan R, et al. Relation of body mass index to transthyretin cardiac amyloidosis particularly in black and Hispanic patients (from the SCAN‐MP study). Am J Cardiol 2022;177:116‐120. doi:10.1016/j.amjcard.2022.05.003
Eldhagen P, Berg S, Lund LH, Sörensson P, Suhr OB, Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med 2021;289:895‐905. doi:10.1111/joim.13222
Mohile SG, Mohamed MR, Xu H, Culakova E, Loh KP, Magnuson A, et al. Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster‐randomised study. Lancet 2021;398:1894‐1904. doi:10.1016/S0140‐6736(21)01789‐X
Cannata F, Chiarito M, Pinto G, Villaschi A, Sanz‐Sánchez J, Fazzari F, et al. Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis. ESC Heart Fail 2022;9:3188‐3197. doi:10.1002/ehf2.13876
Irabor B, McMillan JM, Fine NM. Assessment and management of older patients with transthyretin amyloidosis cardiomyopathy: geriatric cardiology, frailty assessment and beyond. Front Cardiovasc Med 2022;9:863179. doi:10.3389/fcvm.2022.863179
HAS santé (2021). Protocole National de Diagnostic et de Soins (PNDS) Amyloses Cardiaques Filière Cardiogen Centre de référence Amyloses Cardiaques 2020–2021. https://www.has‐sante.fr/upload/docs/application/pdf/2021‐12/pnds_amyloses_cardiaques_v20_version_finale_31082021.pdf. Accessed 6 April 2022.